Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak. The cyclooxygenase-2 selective agents (COXIBS) have an efficacy similar to that of aspirin for most gastrointestinal (GI) lesions but not esophagus. Specifically, there are beneficial short term effects of COXIBs on the risk of colorectal adenoma as shown in the Approve, PreSAP, and APC studies. However, there is still an increased risk of upper GI complications with COXIBs when compared with placebo, and this risk may increase further in some people when aspirin is also consumed. Whereas aspirin reduces the risk of cardiovascular events, COXIBs and most traditional nonsteroidal anti-inflammatory drugs (but not all) are both associated with an increased risk of thrombotic cardiovascular events compared with placebo. In conclusion, COXIBs have a niche role for patients with familial adenomatous polyposis. The value of aspirin remains with respect for efficacy, mainly in the esophagus, and the side effect profile, especially in the elderly if given with acid suppression therapy. COXIBs should be used in younger populations, but if they are considered in the elderly because of increased GI risks, and the cardiovascular risk is also increased, then combination treatment with aspirin and a proton-pump inhibitor should also be considered instead, such as in the ASPECT trial. (Cancer Epidemiol Biomarkers Prev 2008;17(8):1858–61)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“Several large trials, including the APPROVe, APC ADAPT, PreSAP trials, and VICTOR have studied COXIBs for secondary prevention in patients successfully cured of colorectal cancer (35-42).”
BackgroundRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796 · cited 1×
“However, there are two randomized controlled trials that have shown nonsignificant trends in favor of aspirin use (3, 4).”
BackgroundLow dose aspirin and cognitive function in the women's health study cognitive cohort
Kang, J. H., Cook, N., Manson, J., Buring, J. E., & Grodstein, F. (2007) · BMJ · doi:10.1136/bmj.39166.597836.be · Cited by 103 · cited 1×
“Although aspirin has proven efficacy in decreasing the risks of colorectal cancer, cardiac disease, and perhaps also dementia (19), aspirin use is associated with significant morbidity due, in part, to gastric mucosal injury and particularly gastrointestinal (GI) bleeding regardless of preparation (20).”
Background
Cited by
Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Self-citationAspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
Inflammation and colorectal cancer
Kraus, S., & Arber, N. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.006 · Cited by 314
Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., Peng, K., Wu, D., Nurunnabi, M., Nelson, J. A., et al. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10166 · Cited by 42
Metadata
- Authors
- Jankowski, J., & Hunt, R.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2008-08-01
- Volume
- 17
- Issue
- 8
- Pages
- 1858-1861
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2117800515
- Cited by
- 70
- References
- 4
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint. https://app.cochat.ai/papers/10.1158/1055-9965.epi-07-0710
- The paper
- Jankowski, J., & Hunt, R. (2008). Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-07-0710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.